Dr. Sahin presented our recent work on how we take genome/transcriptome-wide approaches to identify regulators of drug resistance, identify mechanisms of resistance and develop novel drug candidates on Feb 12, 2021 at the Seminar Series of Izmir Biomedicine and Genome Center (IBG), which is a leading biomedical center in Turkey.
“Hollings team marks milestone in progress toward investigational new drug for triple-negative breast cancer” https://hollingscancercenter.musc.edu/news/archive/2024/07/22/lox-inhibitor-for-triple-negative-breast-cancer
A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer https://www.sciencedirect.com/science/article/pii/S2451945624002733?via%3Dihub
We participated in the AACR conference with three distinct poster presentations.
0 Comments